Table 1 Clinical characteristics of participants
General n = 252 | General + PECS-2 n = 251 | P value | |
|---|---|---|---|
Age (years) | 52.8 (11.3) | 51.5 (10.4) | 0.180 |
BMI (kg/m2) | 23.6 (7.2) | 24.2 (6.8) | 0.337 |
ASA physical status | |||
I | 144 (57.1) | 137 (54.6) | 0.436 |
II | 75 (29.8) | 87 (34.7) | |
III | 33 (13.1) | 27 (10.8) | |
Oestrogen receptor positive | 210 (83.3) | 199 (79.3) | 0.244 |
Progesterone receptor positive | 174 (69.0) | 183 (72.9) | 0.340 |
HER2 positive | 48 (19.0) | 44 (17.5) | 0.660 |
Ki67 ≥ 30% | 155 (61.5) | 168 (66.9) | 0.205 |
Molecular subtypes | |||
Luminal A | 14 (5.6) | 21 (8.4) | 0.611 |
Luminal B | 158 (62.7) | 149 (59.4) | |
HER2-enriched | 33 (13.1) | 31 (12.4) | |
Triple negative | 47 (18.7) | 50 (19.9) | |
TNM stage | |||
1 | 87 (34.5) | 101 (40.2) | 0.379 |
2 | 117 (46.4) | 103 (41.0) | |
3 | 48 (19.1) | 47 (18.7) | |
Surgery type | |||
Breast conservation | 111 (44.0) | 120 (47.8) | 0.397 |
Mastectomy | 141 (56.0) | 131 (52.2) | |
Surgical duration (min) | 81 (65–124) | 86 (61–136) | 0.466 |
Intraoperative variables | |||
Heart rate (bpm) | 74 (13) | 72 (15) | 0.111 |
MAP (mm Hg) | 90 (8.9) | 91 (9.2) | 0.216 |
Bispectral index score | 50.4 (11.4) | 52.0 (12.0) | 0.126 |
Propofol consumption (mg/kg/h) | 7.2 (1.4) | 7.0 (1.5) | 0.123 |
Remifentanil consumption (μg/kg/h) | 7.8 (3.9) | 6.9 (3.3) | 0.005 |